In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nichi-Iko Pharmaceutical Co. Ltd.

Latest From Nichi-Iko Pharmaceutical Co. Ltd.

Sagent Slides To A Loss, Dragging Down Nichi-Iko’s Margin

An operating loss recorded by its US Sagent affiliate depressed Nichi-Iko’s group operating margin to just 3.7%, even though the Japanese generics specialist’s turnover increased by a tenth on strong domestic generics demand.

Sales & Earnings Japan

International Expansion Stays On Nichi-Iko’s Agenda As Sagent Struggles

Japan’s Nichi-Iko is looking to grow its overseas sales by around a fifth each year, even as its North American injectables affiliate Sagent struggles to move forward and to make a profit.


Business Strategies Japan

Nichi-Iko Looks To File For Interchangeable Infliximab In US Next Year

With a US filing for interchangeable infliximab scheduled for next year, Nichi-Iko is lining up a launch of etanercept in Japan as it seeks alliances to broaden its biosimilars pipeline.


Biosimilars United States

Lupin Paints Better Second Half Riding On Solosec, New US Launch Hopes

Lupin is banking on potential new product introductions and a build-up in sales of Solosec to help drive US growth momentum in the second half of fiscal 2019, but concerns over pipeline weakness persist.
Commercial Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Nichiiko Pharmaceutical Co. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Nichi-Iko Pharmaceutical Co. Ltd.
  • Senior Management
  • Yuichi Tamura, Pres. & CEO
  • Contact Info
  • Nichi-Iko Pharmaceutical Co. Ltd.
    Phone: (81) 76 432 2121
    1-6-21 Sogawa, Toyama-shi
    Toyama, 930-8583